Management of myelodysplastic syndromes in 2019: An update.

This article aims to provide an update on the knowledge that an internist should know for the practical management of myelodysplastic syndromes in 2019. PMID: 31054780 [PubMed - as supplied by publisher]
Source: Revue de Medecine Interne - Category: Internal Medicine Tags: Rev Med Interne Source Type: research

Related Links:

CONCLUSIONS.—: Myelodysplastic syndrome and acute myeloid leukemia in Down syndrome display features that allow discrimination from standard cases of disease. These distinctions are important for treatment decisions, and for understanding disease pathogenesis. We propose specific diagnostic criteria for Down syndrome-related subtypes of acute myeloid leukemia and myelodysplastic syndrome. PMID: 31429606 [PubMed - as supplied by publisher]
Source: Archives of Pathology and Laboratory Medicine - Category: Laboratory Medicine Authors: Tags: Arch Pathol Lab Med Source Type: research
Shwachman-Diamond syndrome (SDS) is a rare and systemic disease mostly caused by mutations in the SBDS gene and characterized by pancreatic insufficiency, skeletal abnormalities and a bone marrow dysfunction. In addition, SDS patients are predisposed to develop myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), typically during adulthood and associated with TP53 mutations. Although most SDS diagnoses are established in childhood, the nature and frequency of serial bone marrow cell investigations during the patients’ lifetime remain a debatable topic. The precise molecular mechanisms leading to AML prog...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Abstract FF-10501 is a novel inhibitor of inosine monophosphate dehydrogenase (IMPDH). Clinical trials of FF-10501 for myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are currently being conducted in the United States. Although it has been shown that FF-10501 induces apoptosis in hematological malignant cells, the intracellular mechanisms of this effect have not been characterized. We conducted an in vitro study to elucidate the mechanisms of FF-10501-induced cell death using 12 hematological malignant cell lines derived from myeloid and lymphoid malignancies. FF-10501 suppressed the growth of eac...
Source: International Journal of Hematology - Category: Hematology Authors: Tags: Int J Hematol Source Type: research
Publication date: Available online 7 August 2019Source: The Lancet HaematologyAuthor(s): Farhad Ravandi, Rita Assi, Naval Daver, Christopher B Benton, Tapan Kadia, Philip A Thompson, Gautam Borthakur, Yesid Alvarado, Elias J Jabbour, Marina Konopleva, Koichi Takahashi, Steven Kornblau, Courtney D DiNardo, Zeev Estrov, Wilmer Flores, Sreyashi Basu, James Allison, Padmanee Sharma, Sherry Pierce, Allison PikeSummaryBackgroundOutcomes for younger patients with acute myeloid leukaemia have moderately improved over the past two decades owing to better supportive care and recent introduction of novel targeted agents. Blocking PD-...
Source: The Lancet Haematology - Category: Hematology Source Type: research
Publication date: Available online 6 August 2019Source: Cancer GeneticsAuthor(s): Prasad Koduru, Weina Chen, Barbara Haley, Kevin Ho, Dwight Oliver, Kathleen WilsonAbstractBreast cancer patients treated with adjuvant chemotherapy regimens containing alkylating agents and anthracyclines are at an increased risk for secondary myeloid malignancies, either acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Complex genomic changes (karyotypes and/or gene amplification) accompany the development of the secondary neoplasms. Here we present a unique case of a breast cancer patient who developed secondary AML within 18...
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
Conditions:   Acute Myeloid Leukemia;   Blasts 20 Percent or More of Bone Marrow Nucleated Cells;   High Risk Myelodysplastic Syndrome;   Recurrent Acute Biphenotypic Leukemia;   Recurrent Acute Myeloid Leukemia;   Recurrent High Risk Myelodysplastic Syndrome;   Refractory Acute Myeloid  Leukemia;   Refractory High Risk Myelodysplastic Syndrome Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Drug: Idarubicin;   Drug: Quizartini...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Publication date: Available online 27 July 2019Source: Journal of Geriatric OncologyAuthor(s): Sotirios G. Papageorgiou, Christos K. Kontos, Ioannis Kotsianidis, Paraskevi Karousi, Argyris Symeonidis, Athanasios Galanopoulos, Anthi Bouchla, Eleftheria Hatzimichael, Panagiotis Repousis, Panagiotis Zikos, Nora-Athina Viniou, Elias Poulakidas, Theodoros P. Vassilakopoulos, Panagiotis Diamantopoulos, Despoina Mparmparousi, Eleni Bouronikou, Helen Papadaki, Panayiotis Panayiotidis, Vasiliki Pappa
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 24 July 2019Source: Cancer GeneticsAuthor(s): Hongyu Ni, Xinlai Sun, Yin Xu, Derek Lyle, Paris Petersen, Xianfeng Zhao, Hong Drum, Bei You, Dongfang Liu, Chen Liu, Jie-Gen JiangABSTRACTEmergence of clonal chromosomal abnormalities in Philadelphia chromosome-negative (CCA/Ph-) cells in chronic myeloid leukemia (CML) patients during the treatment with tyrosine kinase inhibitors (TKIs) is an interesting phenomenon. Although previous studies revealed some potential impact of CCA/Ph- on CML patients’ outcome, clinical significance of CCA/Ph- in CML patients remains to be further elucidat...
Source: Cancer Genetics - Category: Cancer & Oncology Source Type: research
Leukemia, Published online: 24 July 2019; doi:10.1038/s41375-019-0520-yRisk of therapy-related myelodysplastic syndrome/acute myeloid leukemia after childhood cancer: a population-based study
Source: Leukemia - Category: Hematology Authors: Source Type: research
Background: Azacitidine (Aza) and donor lymphocyte infusions (DLI) confer survival advantage with improved tolerability for patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) following allogenic stem cell transplantation (SCT).
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Bone Graft | Cytology | Internal Medicine | Leukemia | Myelodysplastic Syndrome | Revlimid | Stem Cell Therapy | Stem Cells | Transplants